Cargando…
Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
Autores principales: | Molina-Cerrillo, Javier, Alonso-Gordoa, Teresa, Carrato, Alfredo, Grande, Enrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671451/ https://www.ncbi.nlm.nih.gov/pubmed/36395352 http://dx.doi.org/10.18632/oncotarget.28312 |
Ejemplares similares
-
Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020) -
Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial
por: de Velasco, Guillermo, et al.
Publicado: (2022) -
Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
por: Karabajakian, Andy, et al.
Publicado: (2022) -
Addendum: Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification
por: Fang, Jennifer S., et al.
Publicado: (2018) -
Addendum
Publicado: (1985)